

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-167 (cancelled).

168 (previously presented). A method of incorporating a synthetic molecule construct of the structure F-S₁-S₂-L into the lipid bi-layer of a cell or a multi-cellular structure including the step:

of contacting a suspension of the cell or multi-cellular structure with the synthetic molecule construct for a time and at a temperature sufficient to allow incorporation where:


F is a mono-, di-, tri- or oligo- saccharide;

S₁ is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl;

S₂ is -CO(CH₂)₂CO-, -CO(CH₂)₃CO-,
-CO(CH₂)₄CO- or -CO(CH₂)₅CO-; and

L is a diacyl- or dialkyl- glycerophospholipid.

169 (previously presented). The method according to claim 168 where the construct includes the substructure:



where:

$n = 3$ to 5 and M is H .

170 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is of human or murine origin.

171 (previously presented). The method according to claim 168 where the concentration of the construct in the suspension is in the range 0.1 to 10 mg/mL.

172 (previously presented). The method according to 168 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 37 °C.

173 (previously presented). The method according to claim 172 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 25 °C.

174 (previously presented). The method according claim 173 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 4 °C.

175 (previously presented). The method according to claim 168 where F is selected from the group consisting of $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal\beta$; $Gal\alpha 1-3Gal\beta$; $Gal\beta$;


Gal α 1-3(Fuc α 1-2)Gal β ; NeuAc α 2-3Gal β ; NeuAc α 2-6Gal β ; Fuc α 1-2Gal β ; Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(Fuc α 1-2Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; NeuAc α 2-3Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; Gal α 1-4Gal β 1-4Glc; GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; GalNAc α 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; and GalNAc β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc.

176 (previously presented). The method according to claim 175 where F is selected from the group consisting of GalNAc α 1-3(Fuc α 1-2)Gal β and Gal α 1-3(Fuc α 1-2)Gal β .

177 (previously presented). The method according to claim 168 where S₁ is 3-aminopropyl.


178 (previously presented). The method according to claim 168 where L is selected from the group consisting of: 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE).

179 (previously presented). The method according to claim 168 where the construct is:




designated A_{tri}-sp-Ad-DOPE (I).

180 (previously presented). The method according to claim 168 where the construct is:




designated A_{tri}-sp-Ad-DSPE (III).

181 (previously presented). The method according to claim 168 where the construct is:




designated B_{tri}-sp-Ad-DOPE (VI).

182 (previously presented). The method according to claim 168 where the construct is:




designated H_{tri}-sp-Ad-DOPE (VII).

183 (previously presented). The method according to claim 168 where the construct is:




designated H_{di}-sp-Ad-DOPE (VIII).

184 (previously presented). The method according to claim 168 where the construct is:




designated Galβ-sp-Ad-DOPE (IX).

185 (previously presented). The method according to claim 168 where the construct is:



designated Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc-sp-Ad-DOPE (XII).

186 (currently amended). The method according to claim 168 where the construct is:



designated Fuca1-2Galβ1-3(Fuca1-4)GlcNAc-sp-Ad-DOPE (XIII).

187 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is a red blood cell.

188-189 (cancelled).